Key facts
- PCVX - Vaxcyte, Inc. has 22 insiders with reported activity on this page.
- Net insider value flow over the last year: -$2,138,277.
- Recent transaction rows are available for direct filing-level review.
Insider Transactions Reported by 22 Insiders of Vaxcyte, Inc.
- Symbol
- PCVX on Nasdaq
- Location
- San Carlos, CA
Change
- Buy value: ; sell value: $2,138,276.
- Net share flow: -40,653.
Research use
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$2,138,277.
Buys
$0
Shares: 0
Insiders: 0
Sells
$2,138,277
Shares: 40,653
Insiders: 3
Net
-$2,138,277
Shares: -40,653
Insiders: -3
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 19,287 | $0 | $1,126,414 | -$1,126,414 |
| 3-6 | 0 | 21,366 | $0 | $1,011,863 | -$1,011,863 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Vaxcyte, Inc. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Grant Pickering | CHIEF EXECUTIVE OFFICER, Director | $35,551,596 | Mixed | 09 Mar 2026 | ||
| Jeff Fairman | VP, Research | $22,935,618 | Mixed | 30 Dec 2022 | ||
| Andrew Guggenhime | President And Cfo | $9,334,656 | Mixed | 09 Mar 2026 | ||
| Jim Wassil | Chief Operating Officer | $9,135,242 | -$694,785 | -7.1% | Filing P/S | 01 May 2026 |
| Harpreet S. Dhaliwal | Chief Technical Ops Officer | $4,266,052 | -$454,891 | -9.6% | Mixed | 09 Mar 2026 |
| Mikhail Eydelman | Svp, Gen Counsel & Corp Sec | $3,012,039 | Filing P/S | 05 Mar 2025 | ||
| Elvia Cowan | SVP, Finance & CAO | $1,738,500 | -$988,601 | -36% | Filing P/S | 07 Apr 2026 |
| Peter Hirth | Director | $1,043,024 | Mixed | 06 Jun 2024 | ||
| Halley E. Gilbert | Director | $742,052 | Mixed | 12 Jun 2025 | ||
| Heath Lukatch | Director | $499,264 | Mixed | 12 Jun 2025 | ||
| Michael E. Kamarck | Director | $364,388 | Mixed | 13 Jun 2023 | ||
| Teri Loxam | Director | $296,264 | Mixed | 12 Jun 2025 | ||
| Anne S. Drapeau | Director | $296,264 | Mixed | 12 Jun 2025 | ||
| Carlos V Paya MD | Director | $296,264 | Mixed | 12 Jun 2025 | ||
| Jane Wright-Mitchell | General Counsel | $202,438 | Mixed | 16 Aug 2021 | ||
| Jacks Lee | Director | $133,139 | Mixed | 12 Jun 2025 | ||
| Olivier Brandicourt | Director | $115,580 | Mixed | 15 Jan 2026 | ||
| John Furey | Director | $88,189 | Mixed | 12 Jun 2025 | ||
| Paul Sauer | SVP Process Dev, Manufacturing | Mixed | 30 Dec 2022 | |||
| Emster Kurt von | Director | Mixed | 02 Jun 2021 | |||
| Patrick J. Heron | Director | Mixed | 02 Jun 2021 | |||
| Robert Lorne Hopfner | Director | Mixed | 02 Jun 2021 |
Top shareholders of Vaxcyte, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC |
13D/G
13F
|
Company |
12%
|
16,575,875
|
$1,023,560,281 | +$214,375,746 | 31 Mar 2026 | |
| FMR LLC |
13D/G
13F
|
Company |
11%
|
16,451,061
|
$1,015,853,037 | +$204,901,073 | 31 Mar 2026 | |
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
13F
|
Company |
8.9%
|
12,974,599
|
$801,181,488 | +$624,169 | 31 Mar 2026 | |
| T. Rowe Price Investment Management, Inc. |
13F
13D/G
|
Company |
8.6%
from 13D/G
|
12,126,017
|
$704,643,000 | — | 31 Mar 2026 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
7.6%
from 13D/G
|
10,971,816
|
$637,572,225 | — | 31 Mar 2026 | |
| VANGUARD CAPITAL MANAGEMENT LLC |
13D/G
13F
|
Vanguard Capital Management · Company |
5%
|
7,252,053
|
$421,416,800 | $0 | 31 Mar 2026 | |
| VANGUARD PORTFOLIO MANAGEMENT LLC |
13F
|
Company |
4.3%
|
6,279,545
|
$364,904,360 | — | 31 Mar 2026 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
3.9%
|
5,614,597
|
$326,264,231 | — | 31 Mar 2026 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
3.3%
|
4,793,020
|
$278,522,392 | — | 31 Mar 2026 | |
| STATE STREET CORP |
13F
|
Company |
3%
|
4,440,519
|
$258,038,559 | — | 31 Mar 2026 | |
| Deep Track Capital, LP |
13F
|
Company |
2.9%
|
4,300,000
|
$249,873,000 | — | 31 Mar 2026 | |
| WESTFIELD CAPITAL MANAGEMENT CO LP |
13F
|
Company |
2.5%
|
3,646,138
|
$211,877,079 | — | 31 Mar 2026 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.2%
|
3,201,283
|
$186,061,327 | — | 31 Mar 2026 | |
| Kynam Capital Management, LP |
13F
|
Company |
2%
|
2,922,335
|
$169,816,887 | — | 31 Mar 2026 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
2%
|
2,865,318
|
$166,503,629 | — | 31 Mar 2026 | |
| Caligan Partners LP |
13F
|
Company |
1.4%
|
2,060,719
|
$119,748,381 | — | 31 Mar 2026 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
1.2%
|
1,698,011
|
$98,671,420 | — | 31 Mar 2026 | |
| Polar Capital Holdings Plc |
13F
|
Company |
0.98%
|
1,425,788
|
$82,852,541 | — | 31 Mar 2026 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.96%
|
1,403,948
|
$81,583,418 | — | 31 Mar 2026 | |
| MAVERICK CAPITAL LTD |
13F
|
Company |
0.95%
|
1,377,738
|
$80,060,355 | — | 31 Mar 2026 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.94%
|
1,374,292
|
$79,840,223 | — | 31 Mar 2026 | |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
|
Company |
0.94%
|
1,372,425
|
$79,751,617 | — | 31 Mar 2026 | |
| UBS Group AG |
13F
|
Company |
0.92%
|
1,337,390
|
$77,715,733 | — | 31 Mar 2026 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.87%
|
1,275,036
|
$74,092,342 | — | 31 Mar 2026 | |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.86%
|
1,261,000
|
$73,276,710 | — | 31 Mar 2026 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.83%
|
1,216,843
|
$70,710,747 | — | 31 Mar 2026 | |
| Bellevue Group AG |
13F
|
Company |
0.82%
|
1,190,697
|
$69,191,403 | — | 31 Mar 2026 | |
| Assenagon Asset Management S.A. |
13F
|
Company |
0.8%
|
1,164,813
|
$67,687,283 | — | 31 Mar 2026 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.79%
|
1,144,469
|
$66,505,093 | — | 31 Mar 2026 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.69%
|
1,008,314
|
$55,416,949 | — | 31 Mar 2026 | |
| Aberdeen Group plc |
13F
|
Company |
0.67%
|
978,969
|
$56,887,889 | — | 31 Mar 2026 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
0.67%
|
976,429
|
$56,741,000 | — | 31 Mar 2026 | |
| Eversept Partners, LP |
13F
|
Company |
0.63%
|
924,193
|
$53,704,855 | — | 31 Mar 2026 | |
| Capital Research Global Investors |
13F
|
Company |
0.63%
|
912,688
|
$53,036,300 | — | 31 Mar 2026 | |
| Novo Holdings A/S |
13F
|
Company |
0.59%
|
860,000
|
$49,974,600 | — | 31 Mar 2026 | |
| VANGUARD FIDUCIARY TRUST CO |
13F
|
Company |
0.58%
|
842,273
|
$48,944,484 | — | 31 Mar 2026 | |
| Saturn V Capital Management LP |
13F
|
Company |
0.57%
|
824,532
|
$47,913,555 | — | 31 Mar 2026 | |
| BAUPOST GROUP LLC/MA |
13F
|
Company |
0.55%
|
800,000
|
$46,488,000 | — | 31 Mar 2026 | |
| MORGAN STANLEY |
13F
|
Company |
0.5%
|
735,907
|
$42,763,601 | — | 31 Mar 2026 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.48%
|
700,311
|
$40,695,072 | — | 31 Mar 2026 | |
| Trails Edge Capital Partners, LP |
13F
|
Company |
0.45%
|
662,470
|
$38,496,132 | — | 31 Mar 2026 | |
| Jones Hill Capital LP |
13F
|
Company |
0.44%
|
644,831
|
$37,471,129 | — | 31 Mar 2026 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.43%
|
620,401
|
$36,051,502 | — | 31 Mar 2026 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.39%
|
566,828
|
$32,938,375 | — | 31 Mar 2026 | |
| BOOTHBAY FUND MANAGEMENT, LLC |
13F
|
Company |
0.36%
|
522,019
|
$30,334,524 | — | 31 Mar 2026 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.35%
|
514,577
|
$29,902,069 | — | 31 Mar 2026 | |
| BROWN ADVISORY INC |
13F
|
Company |
0.35%
|
511,701
|
$29,734,945 | — | 31 Mar 2026 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.34%
|
501,857
|
$29,162,910 | — | 31 Mar 2026 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.33%
|
474,526
|
$27,574,691 | — | 31 Mar 2026 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.32%
|
473,363
|
$27,507,124 | — | 31 Mar 2026 |
Recent Insider Transactions by Companies or Individuals for Vaxcyte, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Jim Wassil | PCVX | Common Stock | Sale | -1.38% | $127,870 | $56.83 | -2,250 | 160,744 | 01 May 2026 | Direct |
| Elvia Cowan | PCVX | Common Stock | Sale | -9.38% | $180,000 | $60.00 | -3,000 | 28,975 | 07 Apr 2026 | Direct |
| Elvia Cowan | PCVX | Common Stock | Options Exercise | 10.4% | 3,000 | 31,975 | 07 Apr 2026 | Direct | ||
| Elvia Cowan | PCVX | Stock Option (right to buy) | Options Exercise | -3.12% | -3,000 | 93,068 | 07 Apr 2026 | Direct | ||
| Jim Wassil | PCVX | Common Stock | Sale | -1.36% | $131,476 | $58.43 | -2,250 | 162,994 | 01 Apr 2026 | Direct |
| Elvia Cowan | PCVX | Common Stock | Sale | -6.13% | $105,147 | $55.57 | -1,892 | 28,975 | 17 Mar 2026 | Direct |
| Elvia Cowan | PCVX | Common Stock | Sale | -7.49% | $146,482 | $58.59 | -2,500 | 30,867 | 11 Mar 2026 | Direct |
| Elvia Cowan | PCVX | Common Stock | Options Exercise | 8.1% | 2,500 | 33,367 | 11 Mar 2026 | Direct | ||
| Elvia Cowan | PCVX | Stock Option (right to buy) | Options Exercise | -2.54% | -2,500 | 96,068 | 11 Mar 2026 | Direct | ||
| Jim Wassil | PCVX | Common Stock | Sale | -4.24% | $435,440 | $58.88 | -7,395 | 166,818 | 10 Mar 2026 | Direct |
| Grant Pickering | PCVX | Common Stock | Tax liability | -0.74% | -3,685 | 496,939 | 09 Mar 2026 | Direct | ||
| Andrew Guggenhime | PCVX | Common Stock | Tax liability | -0.97% | -1,021 | 104,395 | 09 Mar 2026 | Direct | ||
| Elvia Cowan | PCVX | Common Stock | Tax liability | -1.58% | -495 | 30,867 | 09 Mar 2026 | Direct | ||
| Jim Wassil | PCVX | Common Stock | Tax liability | -0.56% | -975 | 174,213 | 09 Mar 2026 | Direct | ||
| Harpreet S. Dhaliwal | PCVX | Common Stock | Tax liability | -0.79% | -604 | 75,976 | 09 Mar 2026 | Direct | ||
| Elvia Cowan | PCVX | Common Stock | Tax liability | -1.03% | -326 | 31,362 | 02 Mar 2026 | Direct | ||
| Andrew Guggenhime | PCVX | Common Stock | Tax liability | -0.95% | -1,009 | 105,416 | 02 Mar 2026 | Direct | ||
| Grant Pickering | PCVX | Common Stock | Tax liability | -0.5% | -2,531 | 500,624 | 02 Mar 2026 | Direct | ||
| Harpreet S. Dhaliwal | PCVX | Common Stock | Tax liability | -0.6% | -465 | 76,580 | 02 Mar 2026 | Direct | ||
| Jim Wassil | PCVX | Common Stock | Tax liability | -0.57% | -1,009 | 175,188 | 02 Mar 2026 | Direct | ||
| Elvia Cowan | PCVX | Common Stock | Tax liability | -0.76% | -243 | 31,688 | 28 Feb 2026 | Direct | ||
| Andrew Guggenhime | PCVX | Common Stock | Tax liability | -0.84% | -898 | 106,425 | 28 Feb 2026 | Direct | ||
| Grant Pickering | PCVX | Common Stock | Tax liability | -0.57% | -2,863 | 503,155 | 28 Feb 2026 | Direct | ||
| Harpreet S. Dhaliwal | PCVX | Common Stock | Tax liability | -0.38% | -292 | 77,045 | 28 Feb 2026 | Direct | ||
| Jim Wassil | PCVX | Common Stock | Tax liability | -0.51% | -898 | 176,197 | 28 Feb 2026 | Direct | ||
| Jim Wassil | PCVX | Common Stock | Tax liability | -1.06% | -1,900 | 177,095 | 27 Feb 2026 | Direct | ||
| Jim Wassil | PCVX | Common Stock | Award | 2.93% | 5,102 | 178,995 | 27 Feb 2026 | Direct | ||
| Elvia Cowan | PCVX | Common Stock | Options Exercise | 31.9% | 7,716 | 31,931 | 26 Feb 2026 | Direct | ||
| Elvia Cowan | PCVX | Common Stock | Award | 78.9% | 10,681 | 24,215 | 26 Feb 2026 | Direct | ||
| Elvia Cowan | PCVX | Stock Option (right to buy) | Options Exercise | -7.26% | -7,716 | 98,568 | 26 Feb 2026 | Direct | ||
| Elvia Cowan | PCVX | Stock Option (right to buy) | Award | 17,855 | 17,855 | 26 Feb 2026 | Direct | |||
| Andrew Guggenhime | PCVX | Common Stock | Award | 71.8% | 44,864 | 107,323 | 26 Feb 2026 | Direct | ||
| Andrew Guggenhime | PCVX | Stock Option (right to buy) | Award | 74,993 | 74,993 | 26 Feb 2026 | Direct | |||
| Grant Pickering | PCVX | Common Stock | Award | 26.2% | 105,110 | 506,018 | 26 Feb 2026 | Direct | ||
| Grant Pickering | PCVX | Stock Option (right to buy) | Award | 175,698 | 175,698 | 26 Feb 2026 | Direct | |||
| Harpreet S. Dhaliwal | PCVX | Common Stock | Award | 223.2% | 53,409 | 77,337 | 26 Feb 2026 | Direct | ||
| Harpreet S. Dhaliwal | PCVX | Stock Option (right to buy) | Award | 46,424 | 46,424 | 26 Feb 2026 | Direct | |||
| Jim Wassil | PCVX | Common Stock | Award | 22.6% | 32,045 | 173,893 | 26 Feb 2026 | Direct | ||
| Jim Wassil | PCVX | Stock Option (right to buy) | Award | 53,566 | 53,566 | 26 Feb 2026 | Direct | |||
| Olivier Brandicourt | PCVX | Common Stock | Award | 118.2% | 1,357 | 2,505 | 15 Jan 2026 | Direct | ||
| Olivier Brandicourt | PCVX | Stock Option (right to buy) | Award | 6,750 | 6,750 | 15 Jan 2026 | Direct | |||
| Grant Pickering | PCVX | Common Stock | Gift | -20% | -100,000 | 400,908 | 14 Jan 2026 | Direct | ||
| Andrew Guggenhime | PCVX | Common Stock | Gift | 61,850 | 61,850 | 14 Jan 2026 | See Footnote | |||
| Andrew Guggenhime | PCVX | Common Stock | Gift | -49.8% | -61,850 | 62,459 | 14 Jan 2026 | Direct | ||
| Harpreet S. Dhaliwal | PCVX | Common Stock | Sale | -28.9% | $454,891 | $46.69 | -9,743 | 23,928 | 31 Dec 2025 | Direct |
| Elvia Cowan | PCVX | Common Stock | Gift | -6.88% | -1,000 | 13,534 | 23 Dec 2025 | Direct | ||
| Elvia Cowan | PCVX | Common Stock | Sale | -44.4% | $556,972 | $47.92 | -11,623 | 14,534 | 23 Dec 2025 | Direct |
| Elvia Cowan | PCVX | Common Stock | Tax liability | -1.81% | -482 | 26,156 | 08 Sep 2025 | Direct | ||
| Harpreet S. Dhaliwal | PCVX | Common Stock | Tax liability | -3.45% | -1,204 | 33,670 | 08 Sep 2025 | Direct | ||
| Jim Wassil | PCVX | Common Stock | Tax liability | -1.91% | -2,759 | 141,848 | 08 Sep 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.